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1 Zusammenfassung 
 
Hintergrund: Hochdosis-Chemotherapie (HDC), gefolgt von Autologer 
Stammzelltransplantation (ASZT), wird zur Behandlung haemato-onkologischer 
Erkrankungen eingesetzt. Es ist wenig bekannt über die Auswirkungen dieser 
Therapie auf die Angiogenese. 
Ziel der Arbeit: Wir untersuchten den Effekt der HDC/ASZT auf die 
Plasmakonzentration des anti-angiogenen löslichen Vascular Endothelial Growth 
Factor Receptor 1 (sVEGFR1) und den Effekt der Leukapherisate und der 
Patientenseren auf die Angiogenese des Chorioallantois Membran-Assays (CAM) im 
Hühnerei. 
Material und Methoden: VEGFR1- and CD34-exprimierende Zellen der 
Leukapherisate wurden mittels Flowzytometrie analysiert. Die aus einem alternativen 
Splicing hervorgehenden Isoformen der VEGFR1-mRNA wurden mittels reverse 
transcription PCR quantifiziert. 
Resultate: Die Plasmakonzentrationen von sVEGFR1 waren nach HDC erniedrigt, 
aber signifikant erhöht nach ASZT. Patientenserum vor und nach HDC hatte einen 
proangiogenen Effekt auf den CAM-Assay, aber einen starken antiangiogenen Effekt 
nach ASZT, vergleichbar mit demjenigen von Bevacizumab in therapeutischer 
Konzentration. Leukapherisate enthielten hohe Konzentrationen von sVEGFR1 und 
eine grosse Anzahl von VEGFR+ Neutrophilen Granulozyten, die vermehrt mRNA für 
den löslichen sVEGFR1 exprimierten.  
Schlussfolgerung: Von Neutrophilen Granulozyten exprimierter antiangiogener 
VEGFR1 im Leukapherisat könnte zur therapeutischen Effizienz der ASZT beitragen. 
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2.1 Abstract 
Background: High-dose chemotherapy (HDC) followed by autologous stem cell 
transplantation (ASCT) is used for the treatment of hemato-oncologic malignancies. 
Aim: We measured the effect of HDC/ASCT on plasma concentrations of 
antiangiogenic soluble vascular endothelial growth factor receptor 1 (sVEGFR1) and 
of leukapheresis products (LP) and patient serum on chick chorioallantoic (CAM) 
angiogenesis. 
Materials and Methods: VEGFR1- and CD34-expressing cells of leukapheresis 
products were analyzed by flow cytometry. Alternatively spliced isoforms of VEGFR1 
mRNA were quantified using reverse transcription PCR. Results: Plasma 
concentrations of sVEGFR1 decreased after HDC, but significantly increased after 
ASCT. In the CAM assay, sera of patients elicited a proangiogenic effect before and 
after HDC, but a strong antiangiogenic response after ASCT, comparable to that of 
bevacizumab at therapeutic concentrations. LP contains high concentrations of 
sVEGFR1, and high density of VEGFR1+ neutrophilic granulocytes, in which mRNA 
expression is shifted toward the soluble VEGFR1 isoform. Conclusion: Neutrophil-
derived antiangiogenic sVEGFR1 within the LP may contribute to the therapeutic 
efficacy of ASCT. 
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2.2 Introduction 
Autologous stem cell transplantation (ASCT) after high-dose chemotherapy (HDC) 
emerged as a treatment option for hematologic and oncologic malignancies more 
than fifty years ago (1) and represents the cornerstone for the first-line treatment of 
younger patients with multiple myeloma (2). It is an accepted therapeutic option in 
refractory or relapsed lymphoma (3), relapsed testicular cancer (4), and some forms 
of leukemia (5). 
 
ASCT has also been used for therapeutic angiogenesis in non-oncologic disease, 
such as ischemic cardiac (6-8)  and limb (9) disease, and connective tissue disorders 
(10-12) in order to improve microcirculation, although randomized controlled trials in 
ischemic cardiovascular disease reported conflicting data on its beneficial effects (6-
8). However, there is considerable heterogeneity in the methods of mobilization, 
collection, and storage of autologous stem cells. 
While there is evidence that autologous bone marrow cell transplantation has 
proangiogenic effects in the treatment of ischemic disease (10, 13-15), only little is 
known about the angiogenic potential of ASCT after HDC in the treatment of 
hematologic and oncologic malignancies (16-19). 
 
Physiological and pathological angiogenesis, including tumor angiogenesis, is 
regulated by a balance of pro- and antiangiogenic molecules. When the balance 
shifts in favor of angiogenesis inducers, an angiogenic switch activates the normally 
quiescent vasculature to form new blood vessels (20). Even a short-lived, transient 
angiogenic switch can prime progressive tumor growth (21). A prominent 
proangiogenic signaling circuit involves members of the vascular endothelial growth 
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factor (VEGF) family, in particular VEGFA, and its receptors, VEGFR2 and VEGFR3 
(22). VEGFR1, a receptor of VEGFA and placental growth factor (PGF), has strong 
antiangiogenic activity and its genetic ablation has been shown to be associated with 
excessive angiogenesis (23). PGF has been shown to act as an amplifier of VEGF-
driven angiogenesis (24). Besides being expressed on endothelial cells (25), 
VEGFR1 is also expressed on a variety of other cell types, including neutrophils (26, 
27). Two different isoforms of VEGFR1 arise through alternative splicing: a full-length 
transmembrane protein containing an intracellular tyrosine kinase domain, and a 
truncated soluble form, lacking the transmembrane and tyrosine kinase domains 
(sVEGFR1) (25). Proteolytic cleavage of VEGFR1 may also be involved in the 
generation of sVEGFR-1 (28). VEGFR1 and sVEGFR1 both exert antiangiogenic 
effects by sequestration of VEGF, and through a dominant negative effect by forming 
heterodimers with VEGFR1 and -2 (29). 
 
The aim of this study was to determine the effect of HDC and ASCT on plasma 
concentrations of sVEGFR1, VEGF, and PGF and on angiogenesis. 
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2.3 Materials and Methods 
2.3.1 Patients, blood samples, leukapheresis products, and peripheral blood 
mononuclear cells.  
Patients undergoing HDC and ASCT for the treatment of various cancer types were 
included in the study. The study protocol was approved by the local Ethics 
Commission (University of Zurich approval number EK-1363) and written informed 
consent was obtained from all patients. Patient characteristics are shown in Table I. 
Serum and EDTA plasma samples were taken 6 hours before HDC, 4 hours before 
ASCT, 15 minutes after ASCT, and at the time of hematological reconstitution 
(neutrophil count ≥500/μl). Following stem cell mobilizing chemotherapy and 
stimulation with granulocyte-colony stimulating factor (G-CSF), leukapheresis 
products were collected, supplemented with 10% dimethyl sulfoxide (DMSO) and 
33% RPMI cell culture medium and stored in liquid nitrogen until ASCT. For analysis 
of the leukapheresis products, leukocytes were separated from the leukapheresis 
product by Ficoll gradient centrifugation, washed three times with phosphate buffered 
saline (PBS)/5 mM EDTA and filtered through a 100 μm cell strainer. Peripheral 
blood mononuclear cells (PBMCs) were collected from the blood of cancer patients 
by Ficoll gradient centrifugation.  
 
2.3.2 Quantification of VEGFR1, VEGF, and PGF protein expression by 
enzyme-linked immunosorbent assay (ELISA). 
ELISA for the quantification of VEGFR1, VEGF, and PGF were performed using 
immunoassays from R&D Systems (Abingdon, UK), and concentrations in plasma 
and supernatants/medium expressed as pg/ml, or as pg/mg total protein for VEGFR1 
concentrations in cell lysates. 
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2.3.3 Chick chorioallantoic membrane (CAM) assay for the analysis of 
angiogenesis. 
The CAM from a shell-less chick embryo culture was used as described earlier (30). 
In brief, chicken egg contents with intact yolk and embryo were incubated at 37°C 
and 70% humidity. Methylcellulose disks (usually about 4-7 per CAM) as carriers for 
test samples were placed on the CAM of day 8.5 chick embryos in duplicates and 
inoculated with 10 l of serum (± bevacizumab), leukapheresis product, or freezing 
medium containing DMSO. Bevacizumab (BV) was used at a final concentration of 
500 g/ml. Angiogenesis was compared by stereomicroscopy between non-
inoculated CAM areas and areas inoculated with the appropriate control probes after 
48 h, following the application of 20% intralipid (Fresenius Kabi, Uppsala, Sweden) 
underneath the intact CAM to enhance the vascular contrast, and scored by two 
independent investigators blinded to the experiments: 0, neutral; (+), weak 
stimulation; +, marked stimulation; ++, strong stimulation; (–), weak inhibition; –, 
marked inhibition; – –, strong inhibition of vasculogenesis (31). Sera from healthy 
volunteers were used for comparison. 
 
2.3.4 Magnetic activated cell sorting (MACS) for the separation of CD34- and 
VEGFR1- positive and negative cells from leukapheresis products. 
Leukocytes from leukapheresis products were positively selected for CD34+ cells 
using the CD34 MicroBead Kit according to the manufacturer’s protocol (Miltenyi 
Biotech, Bergisch Gladbach, Germany) and for VEGFR1+ cells using an 
allophycocyanin (APC)-labeled monoclonal mouse-anti-human VEGFR1 antibody 
(R&D Systems) and anti-APC beads (Miltenyi Biotech). 
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2.3.5 Reverse transcription quantitative PCR (RT-qPCR) for quantification of 
the alternatively spliced isoforms of VEGFR1 mRNA. 
RT-qPCR was performed for the quantification of the alternatively spliced mRNA 
isoforms of sVEGFR1 and transmembrane VEGFR1 from snap frozen cells after 
removal of genomic DNA in an ABI PRISM 7700 Sequence Detector (Applied 
Biosystems Inc., Foster City, CA, USA) for 40 cycles. Sequences of primers and 
fluorescent VIC-labeled probes were:  sVEGFR1, 
5’-TGTTGCAGTGCTCACCTCTGATTGTAATTTCTT-3’ (probe), 
5’-GCAAGATTCAGGCACCTATGC-3’ (sense), 
5’-AGATCCGAGAGAAAACAGCCTTT-3’ (antisense); VEGFR1, 
5’-TGCTTCCTGATCTCTGATTGTAATTTCTTTCTTCTG-3’ (probe), 
5’-GCAAGATTCAGGCACCTATGC-3’ (sense), 
5’-CTGAGGTTTCGCAGGAGGTATG-3’ (antisense).  
 
2.3.6 Analysis of full blood counts and leukocyte subfractions with blood cell 
analyzer and cytologic staining. 
Full blood counts from EDTA plasma and leukocyte subfractions from leukapheresis 
products, and CD34 and VEGFR1 positively and negatively selected cells were 
analyzed using an automated blood cell analyzer (ADVIA 120; Siemens, Erlangen, 
Germany) and by cytologic staining of cytospins with May-Grünwald-Giemsa. 
 
2.3.7 Flow cytometric analysis for the analysis of CD34+ and VEGFR1+ cells. 
Leukapheresis products, and CD34 and VEGFR1 positively and negatively selected 
cells of leukapheresis products were stained with a fluorescein isothiocyanate (FITC)-
labeled monoclonal mouse-anti-human CD34 antibody (Miltenyi Biotech) and an 
APC-labeled monoclonal mouse-anti-human VEGFR1 antibody (R&D Systems) and 
subjected to flow cytometric analysis using a FACSCalibur® flow cytometer, 
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CellQuestPro (Becton Dickinson Biosciences, Franklin Lakes, NJ, USA), and WinMDI 
Version 2.9 software (Joseph Trotter, Scripps Research Institute, La Jolla, CA, USA). 
 
2.3.8 Statistics 
Kruskal-Wallis and Mann-Whitney U tests were applied to assess statistical 
significance (P) of the difference between multiple and two groups, respectively. 
Fisher’s r to Z test was performed for the calculation of significance P of correlations. 
P<0.05 was considered significant. 
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2.4 Results 
2.4.1 Plasma VEGFR1 decreased after HDC, but significantly increased after 
ASCT. Plasma PGF, but not VEGF, increased after HDC. 
Median plasma VEGFR1 levels decreased by 13% after HDC, but increased by 33% 
immediately after ASCT. This increase was still apparent after hematological 
reconstitution 11 days after ASCT (Figure 1a and b). Changes in VEGF 
concentrations were not significant at any time point (Figure 1c). In contrast, PGF 
concentrations significantly increased after HDC, but did not further increase after 
ASCT (Figure 1d).  
 
2.4.2 Sera of patients before HDC and ASCT stimulate angiogenesis, while 
sera after ASCT and leukapheresis products inhibit angiogenesis. 
Sera from patients undergoing HDC and ASCT induced increased capillary growth 
and numbers of bifurcations in the CAM assay before HDC, and after HDC/before 
ASCT. After ASCT, sera exhibited less ability to induce capillary growth and 
bifurcations, which was sustained through the time of hematological reconstitution 11 
days later. Overall, the inhibitory effect of ASCT on angiogenesis in the CAM assay 
was comparable to the effect of bevacizumab, a humanized mouse monoclonal 
antibody targeting VEGF, when added to serum obtained before ASCT in a 
concentration in the upper range measured in human serum during clinical trials with 
weekly administration of bevacizumab at therapeutical doses of 10 mg/kg body 
weight. Supernatants of leukapheresis products had strong antiangiogenic effects, 
whereas sera of healthy volunteers, or freezing medium only, containing 10% DMSO, 
did not have any measurable effect on CAM angiogenesis (Figure 2a and b). Intra-
individual increases in plasma VEGFR1 concentrations were negatively associated 
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with angiogenesis, whereas decreases were positively associated. This correlation 
was statistically significant (Figure 3). 
 
2.4.3 Leukapheresis products contain high concentrations of sVEGFR1 and 
VEGFR1 is expressed mostly on CD34– cells. 
To test the hypothesis that elevated levels of sVEGFR1 may be due to the sVEGFR1 
present in the leukapheresis product, we analyzed sVEGFR1 concentrations in 
leukapheresis products. (s)VEGFR1 protein concentrations in supernatant (108 
pg/ml) and cell lysate (136 pg/mg total protein) of leukapheresis products were 
comparable to values measured in PBMCs (73 pg/mg total protein) from other 
donors, but significantly lower than concentrations found in cell lysates and 
supernatants of human umbilical vein endothelial cells (HUVECs) in culture (2232 
pg/mg total protein and 2081 pg/ml, respectively). Because CD34+ cells have been 
reported to express VEGFR1 (32), we sorted cells from leukapheresis products for 
CD34 and VEGFR1 expression by MACS. CD34+ cells expressed significantly less 
VEGFR1 than cells sorted for VEGFR1 expression (Figure 4a). 
 
2.4.4 VEGFR1+ cells in leukapheresis products predominantly express mRNA 
encoding for sVEGFR1. 
RT-qPCR for the mRNAs of soluble sVEGFR1 and transmembrane VEGFR1 in cells 
from leukapheresis products demonstrated that the sVEGFR1:VEGFR1 mRNA ratio 
in the VEGFR1+ cell fraction  was 34:1, compared to a ratio of between 2:1 and 8:1 in 
CD34+, CD34–, and VEGFR1– cells and cultured HUVECs (Figure 4b).  
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2.4.5 Neutrophilic granulocytes are the most abundant cell population in 
leukapheresis products and in the VEGFR-1+ cell fraction of 
leukapheresis products. 
To determine the cell type predominantly expressing VEGFR1 in leukapheresis 
products, we quantified leukocyte subpopulations in leukapheresis products and 
VEGFR1+, VEGFR1–, CD34+, and CD34– sorted cells from leukapheresis products 
using an automated blood cell analyzer. Neutrophils were the predominant cells 
within leukapheresis products. They were not only predominantly found in the 
VEGFR-1+ sorted cell fraction of leukapheresis products, but were also the only cell 
type to show a significant difference in number compared to the VEGFR-1– sorted 
cell fraction (Figure 5a). These results were confirmed by Giemsa staining of the 
cytospin of the sorted cells, where the VEGFR1+ population mainly consisted of 
damaged cells appearing as shadow nuclei of the decaying fragile neutrophilic 
granulocytes (not shown). 
Flow cytometric analysis of leukapheresis products, CD34+, CD34–, VEGFR1+, and 
VEGFR1– sorted cells confirmed that CD34+ cells were mainly VEGFR1–, except for 
a small subpopulation, possibly representing endothelial progenitor cells (33). 
VEGFR1+ sorted cells unsurprisingly showed the most uniform VEGFR1+ peak. 
However, VEGFR1+ cells were also found in the VEGFR1– sorted cell fraction (Figure 
5b-f).  
The neutrophilic granulocyte-gated cells showed the same pattern of VEGFR1 
expression as the whole-cell fraction positively or negatively sorted for VEGFR1, 
further corroborating the finding that VEGFR1+ cells in leukapheresis products were 
predominantly neutrophilic granulocytes (Figure 5g). Although the decrease in 
VEGFR1 plasma concentrations was paralleled by a decrease in neutrophilic 
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granulocytes of 37% in the blood of patients after HDC, the changes in neutrophilic 
granulocytes at the different time points were not statistically significant (not shown). 
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2.5 Discussion 
The effects of HDC and ASCT on angiogenesis have not yet been studied. In this 
study, we demonstrate that sVEGFR1, a strong endogenous inhibitor of VEGF 
activity, is found at high concentrations in leukapheresis products and in serum of 
patients after ASCT, and changes in VEGFR1 plasma concentrations correlate with 
the inhibitory effect on angiogenesis on the CAM. The cells most abundantly 
expressing VEGFR1 in leukapheresis products are neutrophils and in these cells, 
VEGFR1 mRNA splicing is shifted toward the expression of the soluble isoform. 
While several endogenous inhibitors of angiogenesis (20) exist, VEGFR1 and its 
soluble isoform sVEGFR1 are among the strongest endogenous inhibitors of 
angiogenesis, acting directly on VEGF via sequestration of circulating VEGF and 
through a dominant negative effect by forming heterodimers with VEGFR1 and -2 
(29). PGF has been shown to act as an amplifier of VEGF-driven angiogenesis (24). 
The changes in plasma VEGFR1 in our study, together with the finding that plasma 
VEGF is unchanged before and after HDC, and ASCT, respectively, and a lack of 
PGF increase after ASCT are consistent with a proangiogenic pattern after HDC, and 
an antiangiogenic pattern after ASCT. Tachi et al. observed an increase in VEGF 
serum levels over 3 months after bone-marrow mononuclear cell implantation for 
critical severe limb ischemia (14), while Sasaki et al. reported a decrease of 
proangiogenic factors in a patient with multiple myeloma following chemotherapy and 
peripheral ASCT (18). Interestingly, an increase in bone marrow endothelial colonies 
after HDC, and a significant reduction of their number after ASCT was observed in 
non-Hodgkin’s lymphoma patients, corroborating an antiangiogenic response of 
ASCT also on a cellular level (16). A decrease in microvessel density after ASCT has 
been described in multiple myeloma (17) although this finding is not consistent (34). 
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The source of sVEGFR1 in the blood of patients after ASCT for ischemic disease has 
been attributed to endothelial progenitor cells, which have been demonstrated to be 
increased after chemotherapy (33, 35) and ASCT (15). However, in our experience 
the CD34+ cell fraction (including endothelial progenitor cells) may be as low as 1-2% 
of all cells within the leukapheresis product, if no CD34+ enrichment procedure is 
performed, and one may wonder therefore if it is a major source of sVEGFR1. 
Stimulation of angiogenesis after HDC is not an unexpected finding, as recent 
studies reported changes consistent with an angiogenic switch after cytotoxic 
systemic chemotherapy (35, 36). There are only few clinical studies addressing the 
functional effects of ASCT on angiogenesis. Most studies have been performed in 
patients with ischemic digits or limbs due to connective tissue or vascular disease, 
and in patients with cardiac ischemic disease. Functional outcomes in these studies 
were measured by angiography, and variable rates of improved perfusion were 
reported, which can be considered a proangiogenic effect, or more precisely, 
vascular remodeling and arteriogenesis (6-8). However, the methods of autologous 
stem cell collection were considerably heterogenous in such studies, using only 
positively selected CD34+ cells from peripheral leukapheresis after recombinant 
human G-CSF with (13) or without (37) previous cyclophosphamide as a mobilization 
regimen, using mononuclear cells from bone marrow aspirate that contain only 0.5% 
CD34+ cells (10), or using recombinant human G-CSF-stimulated cells from direct 
bone marrow aspiration without further processing (11). Furthermore, there are no 
functional data on the potentially distinct effect of the co-infused non-cellular 
components of the leukapheresis product on angiogenesis. It is possible that cellular 
and non-cellular components of leukapheresis products have distinct and maybe 
even opposing effects on angiogenesis. 
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There are several explanations for the proangiogenic effect of serum from patients 
before HDC. All patients in our study received a cytotoxic chemotherapy and 
recombinant human G-CSF for stem cell mobilization shortly before ASCT, either as 
a previous chemotherapy cycle or as a separate regimen in patients with multiple 
myeloma. Chemotherapy itself could therefore be the cause of increased 
angiogenesis. However, given that all of our patients undergoing HDC/ASCT suffered 
from active cancer, the stimulatory effect of serum on CAM angiogenesis before HDC 
might also be explained by tumors eliciting proangiogenic responses (35, 36). G-CSF 
has been shown to promote angiogenesis (38) via the release of VEGF from 
neutrophils (39). Interestingly, however, the administration of recombinant human G-
CSF did not result in a proangiogenic response to serum in the CAM assay in the six 
out of seven patients receiving it from the day before ASCT until hematological 
reconstitution (40).  
Leukapheresis products contained high concentrations of sVEGFR1. To our surprise, 
the cells expressing the highest concentrations of VEGFR1 in leukapheresis products 
were not CD34+ cells. Lysates of VEGFR1 positively selected cells expressed almost 
5 times more VEGFR1 than CD34 positively selected cells, while the expression of 
VEGFR1 was not significantly different between CD34 positively and VEGFR1 
negatively selected cells. VEGFR1 is expressed on many different cell types, 
including neutrophils (25-27, 32, 41-44). VEGF-dependent neutrophil migration has 
been demonstrated to be mediated by VEGFR1, in analogy to similar findings in 
monocytes (26, 42). For monocytes it has been shown that GM-CSF-induced 
sVEGFR1 expression inhibits angiogenesis (45). Given the abundance of neutrophils 
in leukapheresis products in our study, it seems likely that neutrophils are a major 
source of VEGFR1 after ASCT. In our study, neutrophils were the most abundant cell 
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type in leukapheresis products, and only neutrophils showed a significant difference 
in number when leukapheresis products were positively and negatively selected for 
VEGFR1-expressing cells, further corroborating that overall, this cell type is the 
predominant cell type expressing VEGFR1. 
However, the sole expression of transmembrane VEGFR1 by neutrophils does not 
yet explain the increase in soluble plasma sVEGFR. We speculated that a cell type, 
which predominantly expresses VEGFR1 would also be a major source of sVEGFR1, 
if the mRNA ratio of the differentially spliced isoforms sVEGFR1:VEGFR1 was not 
smaller than that of other VEGFR1-expressing cell types. In our study, the mRNA 
ratio of the differentially spliced isoforms sVEGFR1:VEGFR1 showed a shift in favor 
of the expression of sVEGFR1 in VEGFR1 positively selected cells, which we have 
demonstrated to consist mainly of neutrophils. Indeed, a reciprocal relationship of 
sVEGFR1 and VEGFR1 has been proposed for the modulation of responsiveness to 
VEGF in monocytes and neutrophils (26, 46).  
Using flow cytometric analysis, we confirmed that CD34+ sorted cells are mainly 
VEGFR1–, with only a small population expressing VEGFR1. As CD34+ cells have 
been shown to express VEGFR1 (32), the small fraction of VEGFR1+ CD34 positively 
sorted cells was unexpected, but might represent endothelial progenitor cells (33). 
While VEGFR1+ sorted cells naturally exhibited a strong and uniform VEGFR1+ peak, 
VEGFR1 negatively sorted cells also exhibited a VEGFR-1+ peak, albeit smaller. This 
can be technically explained by the possibility that VEGFR1 may be a weaker 
epitope for magnetic cell sorting, resulting in contamination of the VEGFR1– flow-
through. When the cells were analyzed according to their typical scatter pattern 
(granulocyte gate), virtually all VEGFR1+ cells proved to be granulocytes. The results 
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of cytologic and automated cell analysis confirmed the expected distribution, with 
>90% of the granulocyte population being neutrophilic granulocytes. 
In conclusion, the efficiency of HDC followed by ASCT is believed to result from the 
fact that due to the re-infusion of bone marrow stem cells, the time to hematologic 
recovery can be shortened and chemotherapy can be applied at higher doses than 
hematologic toxicity resulting in prolonged aplasia and associated morbidity and 
mortality would normally allow. In this study, we provide evidence that ASCT after 
HDC can exert an antiangiogenic effect, possibly mediated via VEGFR1 derived from 
neutrophils in the leukapheresis product. Although a number of other factors, which 
have not yet been explored, could contribute to the antiangiogenic effects observed, 
our findings could have important implications for manipulative strategies in ASCT, 
e.g. CD34+ enrichment by purging. Consequently, application of neutrophil depletion 
techniques might result in a diminished beneficial antiangiogenic effect. Given the 
differences in the methodology of stem cell collection, a better understanding of the 
heterogeneity regarding the composition of leukapheresis products might explain the 
sometimes contradictory results in therapeutic angiogenesis and could help 
improving the outcome of ASCT in the treatment of hematologic and oncologic 
malignancy and ischemic disease. 
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2.8 Figure legends 
2.8.1 Figure 1 
Enzyme-linked immunosorbent assays for the analysis of plasma concentrations of 
vascular endothelial growth factor receptor-1 (VEGFR1) (a, percentage change; b, 
plasma concentration), vascular endothelial growth factor (VEGF) (c), and placental 
growth factor (PGF) (d) in seven patients. *P<0.05. 
 
2.8.2 Figure 2 
Chick chorioallantoic membrane (CAM) assays (magnification x12.5) with semi-
quantitative angiogenesis scores at the bottom of each photograph (a) and bar charts 
with semi-quantitative angiogenesis scores of CAM duplicates, based on the number 
of bifurcations which are compared between the center and outside of the 
methylcellulose disks (white dotted line) (b). A-C: Sera at the designated time points; 
D: sera incubated in vitro with bevacizumab (500 μg/ml final concentration); E: 
supernatant of leukapheresis products; F: freezing medium including 10% DMSO 
and 33% RPMI cell culture medium. 
 
2.8.3 Figure 3 
Correlation between percentage changes in plasma VEGFR1 concentrations and the 
pro-/antiangiogenic effects in the CAM of the corresponding sera from seven patients 
at four different time points (n=28; note that some dots overlap and may not be 
distinguished well from each other). 
 
2.8.4 Figure 4 
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a: Enzyme-linked immunosorbent assay of (s)VEGFR1 in whole leukapheresis 
products (apheresate) and in CD34 and VEGFR1 positively and negatively selected 
cells from apheresis products, respectively, compared to peripheral blood 
mononuclear cells (PBMC) and human umbilical vein endothelial cells (HUVEC). 
*P<0.05. b: mRNA expression of the alternatively spliced variants of VEGFR1 (i.e. 
the soluble sVEGFR1 and the transmembrane VEGFR1) in VEGFR1 positively 
selected cells from apheresis products. n=4 for each experiment (mean ± SEM). 
 
2.8.5 Figure 5 
a: Automated blood cell analysis of leukocyte subfractions within leukapheresis 
products. n=4 (mean ± SEM). *P<0.05. Flow cytometric analysis of a leukapheresis 
product (b), CD34+ (c), CD34– (d), VEGFR1+ (e), and VEGFR1– (f) magnetic activated 
sorted cells. g: Percentage of VEGFR-1+ cells in all cells vs. cells gated for 
neutrophilic granulocytes in leukapheresis products are shown. n=4 (mean ± SEM). 
*P<0.05. 
 
2.9 Tables and Figures 
2.9.1 Table 1. Patient characteristics 
Patient 
number Gender Diagnosis 
Chemotherapy   (conditioning 
regimen) Dexamethasone* G-CSF†
1 Female Multiple myeloma Melphalan Yes No 
2 Male T-Cell lymphoma, relapsed BEAM Yes Yes 
3 Female Hodgkin lymphoma, relapsed BEAM Yes Yes 
4 Female Multiple myeloma Melphalan Yes Yes 
5 Female AML M5 Busulfan/cyclophosphamide No Yes 
6 Male Multiple myeloma Melphalan Yes Yes 
7 Female Multiple myeloma Melphalan Yes Yes 
*Given during and/or after chemotherapy. †Given before autologous stem cell 
transplantation. 
BEAM: carmustine (BiCNU), etoposide, cytarabine (arabinoside), melphalan; AML: acute 
myeloid leukemia; G-CSF: granulocyte-colony stimulating factor. 
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